EMA Authorised: Carbaglu (carglumic acid) — Tour Hekla

View source ↗

Summary

The European Medicines Agency has authorised Carbaglu (carglumic acid) for propionic acidemia; the marketing authorization holder is Tour Hekla.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Propionic Acidemia

Drugs mentioned

• Carbaglu (carglumic acid)

Snippet

Status: Authorised. Therapeutic area: Amino Acid Metabolism, Inborn Errors;Propionic Acidemia. MAH: Tour Hekla. Decision date: 25/11/2025